TY - JOUR ID - 30352 TI - Anti-VEGF Therapy with Bevacizumab - Limited Cardiovascular Toxicity JO - Asian Pacific Journal of Cancer Prevention JA - APJCP LA - en SN - 1513-7368 Y1 - 2014 PY - 2014 VL - 15 IS - 24 SP - 10769 EP - 10772 KW - Anti-VEGF therapy KW - Bevacizumab KW - cardiovascular toxicity DO - N2 - Purpose: This analysis was conducted to evaluate cardiovascular toxicity of commonly used anti-VEGFtherapeutic agent, bevacizumab, in treating patients with cancer. Methods: Clinical studies evaluating the efficacyand safety of bevacizumab-based regimens on response and safety for patients with cancer were identified usinga predefined search strategy, allowing cardiovascular toxicity and other side effects of treatment to be estimated.Results: In bevacizumab based regimens, 4 clinical studies including 282 patients with advanced cancer (includinggliomas, cervical, breast and ovarian cancer) were considered eligible for inclusion. These bevacizumab-basedregimens included docetaxel, irinitecan and carboplatin. Systematic analysis suggested that, of 282 patientstreated by bevacizumab based regimens, hypertension and thrombo-embolism occurred in 2.5% (7/282), whileonly 3 patients reported cardiovascular events (1.1%). No treatment related death occurred in bevacizumabbased treatment.Conclusion: This systemic analysis suggests that bevacizumab based regimens are associatedwith reasonable and accepted cardiovascular toxicity when treating patients with gliomas, cervical, breast andovarian cancer. UR - https://journal.waocp.org/article_30352.html L1 - https://journal.waocp.org/article_30352_905b72c9261a2281525c2e977c226b66.pdf ER -